|  |
| --- |
| December 15, 2015 |
|  |
| Press contactDr. Edda Schulze Corporate PressPhone +49 201 177-2225Fax +49 201 177-3030edda.schulze@evonik.com  |
| Press contact specialized mediaStefan CornelissenCorporate InnovationPhone +49 201 177-4327Fax +49 201 177-4322stefan.cornelissen@evonik.com |
| Evonik Industries AGRellinghauser Straße 1-1145128 EssenGermanyPhone +49 201 177-01Fax +49 201 177-3475www.evonik.com**Supervisory Board**Dr. Werner Müller, ChairmanExecutive BoardDr. Klaus Engel, ChairmanDr. Ralph Sven KaufmannChristian KullmannThomas WesselUte WolfRegistered Office EssenRegister Court:Essen Local CourtCommercial Registry B 19474VAT ID no. DE 811160003 |

**Enzymes from Evonik to become potential competitors for petroleum**

* Evonik researchers and scientists at Graz University discover biotechnology access to 1-alkenes
* Sophisticated enzyme system as a potential solution
* Biotechnological processes may in future be incorporated into integrated chemical production right from the start of the value chain

Researchers at the specialty chemicals company Evonik Industries, in cooperation with scientists at Graz University, have discovered a biocatalytic access to 1-alkenes such as propene and 1-butene. Such hydrocarbon compounds are considered as key substances for the chemical industry's sophisticated integrated production of high-quality products. For example, Evonik uses propene in the manufacture of superabsorbents or methionine, while 1-butene serves as a component in many types of polyethylene and can be used as a raw material for producing plasticizers.

Such source materials have thus far not been typically manufactured with the aid of biocatalysis. In the opinion of leading scientists, the expansion of biotechnological processes to base, bulk and numerous specialty chemicals remains a largely unresolved challenge to this day. Dr. Thomas Haas, head of the Science & Technology unit at Creavis, Evonik’s strategic innovation unit, says: "If we can succeed in developing technically and economically feasible solutions in this area, we would be able to efficiently combine biotechnological and petrochemical processes in the chemical industry in the form of integrated production for greater added value.”

The industry researchers and the scientists working at Graz University under Professor Kurt Faber achieved a first breakthrough when they used naturally occurring short-chain alkanoic acids—saturated fatty acids produced by bacteria—as the source material for 1-alkenes. Haas notes: "It took the team a year to find an enzyme system for the optimal catalysis of converting the saturated fatty acids to 1-alkenes, ultimately with great success."

An established enzyme system, P450 monooxygenase OleT, catalyzes this chemical reaction—oxidative decarboxylation of alkanoic acids to 1-alkenes—very efficiently and substrate-specifically. Thanks to a cascade of two additional enzyme systems, the required electrons for oxidation are absorbed from oxygen in the air. Haas describes the next steps: "We are now working to transfer our enzyme combination to living cells. However, there is still a lot of work to do before we are ready for industry-scale production."

Haas and his team are consistently pursuing the goal of making renewable resources usable for the chemical industry with the help of biotechnology processes. “We will only be able to make equal use of fossil and biogenic raw material streams if we can find a way to incorporate biotechnological processes into integrated chemical production. This will help maintain and expand the industry's established and efficient value chains,” he explains.

Further information can be found in the new issue 53 of *elements*, Evonik’s scientific newsletter:

<http://corporate.evonik.com/en/media/publications/elements/Pages/default.aspx>

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.